Ram Samudrala is Professor and Chief, Division of Bioinformatics, State University of New York, Buffalo researching multiscale modeling of atomic, molecular, cellular, and physiological systems, with an emphasis on protein and proteome structure, function, interaction, design, and evolution. His work has led to more than 115 publications in journals such as Science, Nature, PLoS Biology, the Proceedings of the National Academy of Sciences, and the Journal of the American Medical Association. Samudrala joined the University of Washington faculty in 2001 (where he remains an Affiliate Professor) after completing his doctoral research with John Moult at the Center for Advanced Research in Biotechnology in 1997, and his postdoctoral research with Michael Levitt (2013 Nobel in Chemistry) at Stanford University in 2000, which resulted in him making some of the best predictions at the first three community-wide assessment of protein structure prediction (CASP) experiments. In 2002, he received a Searle Scholar Award which funds exceptional young scientists, was named one of the world's top young innovators (TR100) by MIT Technology Review in 2003, and was selected to present the University of Washington New Investigator Science in Medicine Lecture in 2004.

Molecular and Population Genetics, Developmental Biology, Bacterial Physiology, Plant Structure Function and Systematics, Evolution, Developmental Biology, Chemistry of Nucleic Acids, Protein Chemistry and Enzymic Catalysis, Protein Structure and Function, Cell Biology, and Biophysics and Theoretical/Computational Biology.

Dr. Mead leads the research and development efforts for the Company’s research use only products. He earned a Ph.D. in Physiology and Biophysics at the University of Illinois–Champaign/Urbana. Dr. Mead is the inventor of TA cloning and is the co-author of forty four publications.

protein

John Gu is the President and CSO of Renascions, a precision medicine company in pharmaceutical development. He is an adjunct professor in the Molecular Pharmacology Department at City of Hope, and was a program director at Sidney Kimmel Cancer Center. He received his Ph.D in Chemistry, and was the recipient of the NIH Fellowship for the Human Genome Project at Washington University School of Medicine in St Louis. He worked on the discovery and applications of genome-wide SNPs and built a foundation for high density DNA microarray using in SNP mapping. His scientific focuses include developing clinical applications for GWAS SNP data, and his most recent interest is usingReAL, a proprietary technology, to measure, predict, and improve the clinical outcomes in genetic predisposition subpopulations. ReAL has been used in various clinical programs in collaborations with industrial partners, and has achieved outstanding results. In addition, Renascions is currently working on a T2D drug in clinical stages. Dr. Gu previously worked as a senior scientific staff and section head at Motorola Life Sciences, and as an executive at Vita Genomics, Shanghai GeneCore Biotechnologies, and CytoPharm Therapeutics. He also serves as a board director at Global Oceanic and Parallel 6.

Applications of genome-wide SNPs and built a foundation for high density DNA microarray using in SNP mapping

Dr. Fritzinger is a seasoned molecular biologist and protein chemist with over 25 years experience in both academia and biotech companies, as well as over 10 years experience working on the early-stage development of protein therapeutics. He received his BS in Chemistry from Purdue University and his Ph.D. from the University of Massachusetts at Amherst, where he studied conformational changes in tRNA caused by changes in solution conditions or aminoacylation. Dr. Fritzinger performed his post-doctoral research at the University of Bristol, working in the lab of Nigel Brown on the sequence of the Mercury-resistance transposon, Tn501. Following his post-doc, Dr. Fritzinger held several positions in academia and at biotechnology companies. His last position was as an Associate Professor at the University of Hawaii Cancer Center, where he performed structure/function studies on human complement C3. While at the UH Cancer Center, Dr. Fritzinger was the co-founder of a startup biotech company, InCode Biopharmaceutics, Inc., that was based on the Intellectual Property from his laboratory. Dr. Fritzinger was the Chief Scientific Officer at InCode, where he directed all discovery research for the company and managed the work of both CROs and CMOs in producing large quantities of the company’s lead protein, both in insect and mammalian cells. Previous to his work at UH and InCode, Dr. Fritzinger was the director of the DNA sequencing and genotyping core at Myriad Genetics, Inc. Dr. Fritzinger has started a consulting company, Fritzinger Biopharma Consulting, LLC, where he provides consulting services in molecular biology, protein chemistry, and biologics development.

Protein Therapeutic Drug Development Site-Directed Mutagenesis Protein Structure and Function Contract Research Organization Management Group Leadership Basic Research Applied Research Protein Engineering Protein Expression Protein Purification Group Mentoring Molecular Biology Protein Optimization Laboratory Management DNA Sequencing Molecular Cloning Biochemistry

Victor Tsetlin has received his Ph.D in 1973, from 1996 he is a Professor and from 2006, he is a Corresponding Member of the Russian Academy of Sciences, Head of the Department.
Awards & honors: -Winner of State Prize of USSR -Alexander von Humboldt Prize winner

Neurosignaling, Bioorganic Chemistry,Protein Neurotoxins

Kazuyuki Nakamura is serving for the promotion of human proteomics as a HUPO Council member, a member of Education & Training (E&T) Committee, a co-chair of Human Disease Glycomics Proteome Initiative (HGPI), an advisory member of Human Kidney and Urine Proteome Project (HKUPP), an AOHUPO Vice President (E&T Mission), a member of Membrane Proteomics Initiative (MPI), and a Past President of Japan HUPO. He is active in Education and Training of young scientists in Asia not only as a Member of HUPO E&T Committee and a President of Japanese Electrophoresis Society (JES). He organized a Joint Meeting of AOHUPO symposium and JES symposium for the Satellite Meeting of 20th IUBMB to promote E&T in Japan.

He is interested in the discovery of biomarkers and therapeutic targets for HCV-related Hepatocellular Carcinoma and Pancreatic Cancer using two-dimensional gel electrophoresis combined with tandem mass spectrometry, and in the development of Cys-tag-Protein Chips for high through-put analyses of protein-protein interactions. His interest is shifting to Membrane Proteomics, Cancer Immunology and Immuno-Proteomics for the development of new diagnostic tools and non-invasive curative treatments of malignant tumors.

Cochran has completed his Ph.D in 2005 from the Department of Biological Sciences at the University of Pittsburgh and postdoctoral studies in 2011 from the Department of Chemistry at Dartmouth College. He is currently an Assistant Professor in the Department of Molecular and Cellular Biochemistry at Indiana University. He has published 15 papers in reputed journals and has 4 manuscripts in review at present.

Dr. Cochran research has focused on elucidating the mechanism of unconventional kinesin motors from the kinesin-5 (BimC/Eg5) and kinesin-10 (chromokinesin/NOD) families as well as characterizing non-muscle myosin-2 from Dictyostelium discoideum.

Vincent KL Ip has completed his MD at the age of 26 years from University of Manitoba 1967 and he was trained in Internal Medicine in Winnipeg and Glasgow to obtain degrees of MRCP (UK and Edinburgh). He was a Special Student in the Department of Mathematics Hong Kong Baptist University 2001 to 2006. He initiated his current research in 2004.The work was published in the Journal of Human Virology and Retrovirology.

Virology and Retrovirology

Abdel Aziz Zidane is a Director of Genomics & Proteomics unit, Center of Excellence for Cancer Research (CECR), Tanta University

In vitro conditioning of T cells to acquire phenotypic and functional characteristics with hematopoietic stem cells, Optimizing adjuvanticiy of combinatorial chemotherapy and adoptive immunotherapy, Development of novel delivery strategy for DNA vaccine and cytokines for utilization in cancer and infectious diseases.